stockrow
Friday 6 November 2026
Export CRDL’s income statement to Excel — free account
Cardiol Therapeutics Inc.
CRDL Healthcare Drug Manufacturers Specialty & Generic
- EPS
- +42.9%
- Free cash flow
- +10.6%
- Total debt
- −38.8%
Quarter to June 2026, against a year earlier
0.98
0.05
+5.38%
Follow CRDL
Alert me
Cardiol Therapeutics Inc. (CRDL) P/E ratio
Cardiol Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2021 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CPIX Cumberland Pharmaceuticals Inc. compare | n/m |
| ADCT ADC Therapeutics SA compare | n/m |
| DERM Journey Medical Corporation compare | n/m |
| GLAS Glass House Brands Inc. compare | n/m |
| AKBA Akebia Therapeutics, Inc. compare | n/m |
| ORGO Organogenesis compare | n/m |
| CRDL Cardiol Therapeutics Inc. | n/m |
| OGI Organigram Global Inc. compare | 2.0× |
| BGM BGM Group Ltd. compare | 148× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)